SIGA Technologies, Inc. (NASDAQ:SIGA) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET

Company Participants

Phillip Gomez - CEO & Director

Dennis Hruby - EVP & Chief Scientific Officer

Daniel Luckshire - EVP, CFO & Secretary

Conference Call Participants

Soo Romanoff - Edison Group

Peter Imber - North Point Partners

Operator

Welcome to the SIGA business update call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or changed circumstances after this call.

For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including, without limitation, the company's annual report on Form 10-K for the year ended December 13, 2021 -- excuse me, 2021 and its subsequent reports on Form 10-Q and Form 8-K.

With that said, I'd like to turn the call over to Mr. Phil Gomez, your host.

Phillip Gomez

Thank you for taking the time to join today's call. Today, I'm joined by Dan Luckshire, our CFO; and Dr. Dennis Hruby, our CSO. We are pleased to have this opportunity to provide a business, R&D and financial update to our shareholders. We'll then be happy to take questions. With the global monkeypox outbreak, we've been very busy over the last approximately 75 days, responding to inquiries from a broad multitude of people and entities across the public health ecosystem as well as building on existing governmental and public health relationships.

One initial result of this activity has been a significant increase in the international procurement orders this year versus 2021 with approximately $60 million of oral TPOXX orders from 10 international jurisdictions this year through July 31 in comparison to approximately $13 million of international orders last year.

Of the 10 international jurisdictions who have ordered oral TPOXX in 2022, 9 of the jurisdictions are first-time customers in 2022. We believe that the increasing number of international governments that are procuring oral TPOXX in addition to the large number of continuing inquiries regarding TPOXX usage for monkeypox and its potential procurement highlight 2 key elements. Firstly, that is essential that governments across the world adopt a more proactive approach to addressing the health risk posed by families of viruses such as the orthopoxvirus family.